These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15012693)

  • 1. Management of secondary hyperparathyroidism of dialysis patients.
    Akizawa T; Kamimura M; Mizobuchi M; Shiizaki K; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S53-7. PubMed ID: 15012693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New strategies for the treatment of secondary hyperparathyroidism.
    Akizawa T; Shiizaki K; Hatamura I; Kamimura M; Mizobuchi M; Narukawa N; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S100-3. PubMed ID: 12612963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.
    Sanchez CP
    Paediatr Drugs; 2003; 5(11):763-76. PubMed ID: 14580225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
    Slatopolsky E; Finch J; Ritter C; Takahashi F
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ; González EA; Gellens ME; Hamm LL; Abboud H; Lindberg J
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
    Joist HE; Ahya SN; Giles K; Norwood K; Slatopolsky E; Coyne DW
    Clin Nephrol; 2006 May; 65(5):335-41. PubMed ID: 16724654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
    Brown AJ; Coyne DW
    Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroidectomy in the Management of Secondary Hyperparathyroidism.
    Lau WL; Obi Y; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2018 Jun; 13(6):952-961. PubMed ID: 29523679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pharmacotherapy for secondary hyperparathyroidism.
    Rodríguez M; Rodríguez-Ortiz ME
    Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
    Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients.
    Kitaoka M; Fukagawa M; Ogata E; Kurokawa K
    Kidney Int; 1994 Oct; 46(4):1110-7. PubMed ID: 7861705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.